Published in Br J Cancer on April 01, 1999
Role of the retinoic acid receptor-α in HIV-associated nephropathy. Kidney Int (2010) 1.89
Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc Natl Acad Sci U S A (2000) 1.60
Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A (2000) 1.23
Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol (2006) 1.22
Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation. J Biol Chem (2012) 1.21
Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp Nephrol (2012) 1.17
A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer (2003) 1.08
Retinoic acid utilizes CREB and USF1 in a transcriptional feed-forward loop in order to stimulate MKP1 expression in human immunodeficiency virus-infected podocytes. Mol Cell Biol (2008) 1.07
Opposing cytokine-specific effects of all trans-retinoic acid on the activation and expression of signal transducer and activator of transcription (STAT)-1 in THP-1 cells. Immunology (2002) 1.06
Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep (2015) 0.98
Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One (2011) 0.95
The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer (2005) 0.94
Retinoid-mediated inhibition of interleukin-12 production in mouse macrophages suppresses Th1 cytokine profile in CD4(+) T cells. Br J Pharmacol (2000) 0.93
The Retinoic Acid Receptor-alpha mediates human T-cell activation and Th2 cytokine and chemokine production. BMC Immunol (2008) 0.92
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure. Kidney Int (2012) 0.91
Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells. Exp Biol Med (Maywood) (2007) 0.90
Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol (2010) 0.89
Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer. Am J Pathol (2001) 0.89
Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide. Mol Cell Biochem (2009) 0.88
Retinoic acid has different effects on UCP1 expression in mouse and human adipocytes. BMC Cell Biol (2013) 0.83
Role of retinoic receptors in lung carcinogenesis. J Exp Clin Cancer Res (2008) 0.81
Cortical and trabecular bone, bone mineral density, and resistance to ex vivo fracture are not altered in response to life-long vitamin A supplementation in aging rats. J Nutr (2011) 0.80
The beneficial role of retinoids in glomerular disease. Front Med (Lausanne) (2015) 0.79
Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol (2007) 0.79
Induction of retinol dehydrogenase 9 expression in podocytes attenuates kidney injury. J Am Soc Nephrol (2014) 0.78
Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells. BMC Cancer (2014) 0.77
Altered function of peripheral organ systems in rats exposed to chronic mild stress model of depression. Cell Mol Neurobiol (2001) 0.76
Association study between novel CYP26 polymorphisms and the risk of betel quid-related malignant oral disorders. ScientificWorldJournal (2015) 0.76
Downregulation of retinoic acid receptor-beta(2) expression is linked to aberrant methylation in esophageal squamous cell carcinoma cell lines. World J Gastroenterol (2004) 0.75
α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid. Med Sci Monit (2016) 0.75
Retinoic acid improves nephrotoxic serum-induced glomerulonephritis through activation of podocyte retinoic acid receptor α. Kidney Int (2017) 0.75
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 12.02
A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature (1995) 11.18
Zinc fingers: gilt by association. Cell (1988) 9.21
A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature (1988) 9.07
Identification of a receptor for the morphogen retinoic acid. Nature (1988) 8.32
p53 status and the efficacy of cancer therapy in vivo. Science (1994) 6.72
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood (1988) 6.09
Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature (1992) 5.76
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev (1992) 4.69
Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors. Nature (1992) 4.44
All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 4.36
Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature (1995) 3.90
A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell (1991) 3.87
p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell (1994) 3.69
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 3.69
Evolution of the nuclear receptor gene superfamily. EMBO J (1992) 3.55
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med (1991) 3.52
Nuclear receptor coactivators and corepressors. Mol Endocrinol (1996) 3.44
The role of the vitamin D endocrine system in health and disease. N Engl J Med (1989) 3.37
Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A (1993) 2.96
Promoter context- and response element-dependent specificity of the transcriptional activation and modulating functions of retinoic acid receptors. Cell (1992) 2.50
All-trans and 9-cis retinoic acid induction of CRABPII transcription is mediated by RAR-RXR heterodimers bound to DR1 and DR2 repeated motifs. Cell (1992) 2.49
Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev (1994) 2.27
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med (1993) 2.10
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res (1994) 1.94
13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med (1986) 1.90
Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol (1993) 1.84
Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst (1995) 1.83
Multiple parameters control the selectivity of nuclear receptors for their response elements. Selectivity and promiscuity in response element recognition by retinoic acid receptors and retinoid X receptors. J Biol Chem (1993) 1.77
HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin Exp Immunol (1990) 1.77
A retinoic acid response element is present in the mouse cellular retinol binding protein I (mCRBPI) promoter. EMBO J (1991) 1.74
All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood (1995) 1.66
Retinoids in cancer chemoprevention. FASEB J (1996) 1.60
Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene (1995) 1.60
Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem (1996) 1.58
The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol (1994) 1.58
Two distinct actions of retinoid-receptor ligands. Nature (1996) 1.55
Prevention of second primary tumours with etretinate in squamous cell carcinoma of the oral cavity and oropharynx. Results of a multicentric double-blind randomised study. Eur J Cancer (1994) 1.51
Anatomy of the steroid receptor zinc finger region. Endocr Rev (1992) 1.44
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res (1992) 1.28
Characterization of DNA binding and retinoic acid binding properties of retinoic acid receptor. Proc Natl Acad Sci U S A (1991) 1.26
Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res (1996) 1.25
Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res (1996) 1.25
Nuclear receptors in Sicily: all in the famiglia. Cell (1997) 1.22
Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol (1994) 1.18
A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood (1991) 1.17
p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene (1995) 1.16
Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol (1995) 1.13
Retinoic acid activates interferon regulatory factor-1 gene expression in myeloid cells. Blood (1996) 1.13
Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res (1994) 1.12
Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function. Mol Cell Endocrinol (1993) 1.10
Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer (1996) 1.10
Ligand-dependent occupancy of the retinoic acid receptor beta 2 promoter in vivo. Mol Cell Biol (1994) 1.08
EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol (1992) 1.08
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res (1994) 1.06
The cellular retinoic acid binding protein I is dispensable. Proc Natl Acad Sci U S A (1994) 1.05
Activation of retinoid X receptors induces apoptosis in HL-60 cell lines. Mol Cell Biol (1995) 1.05
Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res (1996) 1.05
Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (1997) 1.04
Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res (1994) 1.04
Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation. Exp Cell Biol (1987) 1.03
Suppression of squamous cell carcinoma growth and differentiation by retinoids. Cancer Res (1994) 1.03
Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res (1996) 1.03
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells. J Biol Chem (1996) 1.02
WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene (1996) 1.02
Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res (1996) 1.01
Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst (1994) 1.00
Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factor-beta. Cancer Surv (1992) 0.99
Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-alpha acquire sensitivity to growth inhibition by retinoids. J Biol Chem (1994) 0.99
The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog Horm Res (1995) 0.98
N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis (1995) 0.97
Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res (1993) 0.97
Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer (1996) 0.96
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines. Br J Cancer (1997) 0.94
All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med (1994) 0.93
Phenotype-specific "tissue" transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int J Cancer (1992) 0.92
Effects of topical tretinoin on dysplastic nevi. J Clin Oncol (1994) 0.91
Apoptosis during retinoic acid-induced differentiation of F9 embryonal carcinoma cells. Exp Cell Res (1994) 0.90
Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene (1995) 0.90
Highlights of the cancer chemoprevention studies in China. Prev Med (1993) 0.89
Multi-institutional study of all-trans-retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukaemia Study Group of the Ministry of Health and Welfare. Leukemia (1993) 0.88
Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer (1995) 0.87
Retinoids in prevention of skin cancer. Cancer Lett (1997) 0.87
The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat (1996) 0.87
Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide. Ann N Y Acad Sci (1995) 0.87
Synergistic antiproliferative effect of human recombinant interferons and retinoic acid in cultured breast cancer cells. J Natl Cancer Inst (1986) 0.87
1 alpha, 25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res (1996) 0.86
Retinoic acid inhibition of human breast carcinoma proliferation is accompanied by inhibition of the synthesis of a Mr 39,000 protein. Cancer Res (1990) 0.86
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86
Effects of retinoic acid and gamma-interferon on expression of retinoic acid receptor and cellular retinoic acid-binding protein in breast cancer cells. Cancer Res (1995) 0.86
Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer (1993) 0.85
Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res (1994) 0.85
Loss of retinoic acid receptors in mouse skin and skin tumors is associated with activation of the ras(Ha) oncogene and high risk for premalignant progression. Cancer Res (1996) 0.84
Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl (1993) 0.84
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol (2002) 4.25
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Management of malignant teratoma: does referral to a specialist unit matter? Lancet (1993) 3.73
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res (1999) 3.24
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res (1989) 2.71
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res (2000) 2.17
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Therapy for testicular cancer in Central and Eastern Europe. Lancet (1990) 2.08
Medical audit, cancer registration, and survival in ovarian cancer. Lancet (1991) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J Clin Oncol (2001) 1.62
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Changes in testicular cancer in Scotland. Eur J Cancer Clin Oncol (1987) 1.58
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol (2002) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Carboplatin or cisplatin? Lancet (1988) 1.53
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group) Eur J Cancer (1991) 1.52
Late spontaneous anterior dislocation of an intraocular lens (IOL) with the capsular bag. Eye (Lond) (2005) 1.52
Collagen corneal shields. Surv Ophthalmol (2002) 1.49
The changing role of surgery in metastatic non-seminomatous germ cell tumour. Br J Cancer (1992) 1.49
Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity. Clin Exp Allergy (2011) 1.45
Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience. Ann Oncol (2012) 1.44
Antiemetic therapy--where do we go from here? Ann Oncol (1993) 1.43
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1983) 1.42
The effect of verapamil on the pharmacokinetics of adriamycin. Cancer Chemother Pharmacol (1986) 1.41
Chemotherapy of advanced malignant teratomas. Br J Cancer (1980) 1.40
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer (1993) 1.36
Fluoroquinolones: place in ocular therapy. Drugs (2001) 1.34
Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients. Br J Cancer (1979) 1.32
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29
Phase I and pharmacokinetic study of rhizoxin. Cancer Res (1992) 1.26
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs. Br Med J (Clin Res Ed) (1985) 1.25
Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res (1987) 1.24
Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol (1999) 1.22
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer (1993) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol (2008) 1.19
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. Br J Cancer (1979) 1.19
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res (1986) 1.19
Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol (1996) 1.18
Drug resistance reversal--are we getting closer? Eur J Cancer (2003) 1.18
Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res (1993) 1.18
Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev (2000) 1.17
On the receiving end--II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol (1983) 1.17
Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer (1995) 1.16
Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Report of two cases. Support Care Cancer (2001) 1.16
P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer (1990) 1.15
Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil. Br J Cancer (1989) 1.14
Chart for visual acuity screening. Br J Ophthalmol (1989) 1.14
VP16-213 as a single agent in advanced testicular tumors. Eur J Cancer (1980) 1.13
Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol (1984) 1.11
Gemcitabine: current status of phase I and II trials. J Clin Oncol (1994) 1.11
Cross-resistance to cytotoxic drugs in human glioma cell lines in culture. Br J Cancer (1984) 1.10
Pneumocystis pneumonia. Br Med J (Clin Res Ed) (1983) 1.10
Resistance of human glioma to adriamycin in vitro: the role of membrane transport and its circumvention with verapamil. Br J Cancer (1986) 1.10
The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol (1990) 1.10
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer (1997) 1.09
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat Rev (2010) 1.09
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer (1989) 1.08
Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol (1997) 1.07
From darkness to light with biomarkers in early clinical trials of cancer drugs. Clin Pharmacol Ther (2009) 1.06
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. Br J Cancer (2012) 1.06
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Natl Cancer Inst (1995) 1.05
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. Br J Surg (1984) 1.04
Cervical carcinoma: a drug-responsive tumor--experience with combined cisplatin, vinblastine, and bleomycin therapy. Gynecol Oncol (1983) 1.02
Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol (1984) 1.02
Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer (1986) 1.02
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer (2013) 1.02
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1986) 1.01
Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer (1995) 1.00
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? Br J Cancer (1994) 1.00
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. Eur J Cancer Clin Oncol (1988) 1.00
Response of differentiated but not anaplastic teratoma to interferon. Br J Cancer (1984) 1.00
Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother Pharmacol (1987) 0.99
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer (2001) 0.99
Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol (2000) 0.98
Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol (2006) 0.98
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer. Int J Cancer (1994) 0.97
Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol (2005) 0.96
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer (1994) 0.96
Hepatocellular and gastric carcinoma associated with familial polyposis coli. J Surg Oncol (1988) 0.96
A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer (1992) 0.96
Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. Br Med J (1978) 0.96
Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer (1998) 0.95